Recent Finacing
Recent Raise
Apexian Pharmaceuticals is a clinical-stage biotech developing oral inhibitor APX3330 targeting APE1/Ref-1 to modulate HIF‑1α/STAT3/NF‑κB/AP‑1 and restore neuronal DNA repair, pursuing cancer and CIPN studies.
Focus Areas
Recent Investors
Funding round
Investor